{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.6","value":"145"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"420"}],"units":"Participants"}],"title":"Cycle 1 Day 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.3","value":"215"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"373"}],"units":"Participants"}],"title":"Cycle 2 Day 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.3","value":"245"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"343"}],"units":"Participants"}],"title":"Cycle 3 Day 27"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"111","value":"274"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"title":"Cycle 7 Day 27"}],"denoms":[{"counts":[{"groupId":"OG000","value":"420"}],"units":"Participants"}],"description":"Minimum serum concentration for atezolizumab.","dispersionType":"Standard Deviation","groups":[{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study medication and who have at least one post-baseline PK sample available.","reportingStatus":"POSTED","timeFrame":"Day 27 of Cycle 1, 2, 3, and 7 (Cycle = 28 days)","title":"Minimum Serum Concentration (Cmin) for Atezolizumab","type":"SECONDARY","unitOfMeasure":"µg/mL"}